Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Death/hospitalization/c.. 24% Improvement Relative Risk HCQ for COVID-19  Ladapo et al.  META ANALYSIS c19hcq.org Favors HCQ Favors control

Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis

Ladapo et al., medRxiv, doi:10.1101/2020.09.30.20204693
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Meta analysis of prophylactic and early treatment RCTs, 24% reduction in cases, hospitalization or death with HCQ, RR 0.76, p=0.025. No serious adverse cardiac events were reported. 5,577 patients.
The Boulware study provides a breakdown for treatment delay. For the case of < ~4 days (2 days enrollment, ~46 hours shipping), the result of the meta analysis becomes RR 0.68, p=0.0097.
The actual effect may be larger due to treatment delays, followup loss, protocol deviation, active placebos, no severity analysis for cases, and suboptimal regimens.
For the individual studies see Boulware, Mitjà, Mitjà (B), Rajasingham, Skipper.
7 meta analyses show significant improvements with hydroxychloroquine for mortality Landsteiner de Sampaio Amêndola, Risch, Risch (B), Stricker, hospitalization Landsteiner de Sampaio Amêndola, recovery Prodromos, combined death/hospitalization/cases Ladapo, and cases García-Albéniz.
Currently there are 38 HCQ for COVID-19 early treatment studies, showing 76% lower mortality [60‑86%], 67% lower ventilation [-710‑99%], 31% lower ICU admission [1‑53%], and 41% lower hospitalization [28‑51%].
risk of death/hospitalization/cases, 24.0% lower, RR 0.76, p = 0.03.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ladapo et al., 30 Sep 2020, preprint, 4 authors.
This PaperHCQAll
Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis
MD, PhD Joseph A Ladapo, MD, MSc John E Mckinnon, MD, MPH Peter A Mccullough, MD, PhD Harvey A Risch
doi:10.1101/2020.09.30.20204693
Objective-To determine if hydroxychloroquine (HCQ) reduces the incidence of new illness, hospitalization or death among outpatients at risk for or infected with SARS-CoV-2 (COVID-19). Design-Systematic review and meta-analysis of randomized clinical trials. Data sources-Search of MEDLINE, EMBASE, PubMed, medRxiv, PROSPERO, and the Cochrane Central Register of Controlled Trials. Also review of reference lists from recent meta-analyses. Study selection-Randomized clinical trials in which participants were treated with HCQ or placebo/standard-of-care for pre-exposure prophylaxis, post-exposure prophylaxis, or outpatient therapy for COVID-19. Methods-Two investigators independently extracted data on trial design and outcomes. Medication side effects and adverse reactions were also assessed. The primary outcome was COVID-19 hospitalization or death. When unavailable, new COVID-19 infection was used. We calculated random effects meta-analysis according to the method of DerSimonian and Laird. Heterogeneity between the studies was evaluated by calculation of Cochran Q and I 2 parameters. An Egger funnel plot was drawn to investigate publication bias. We also calculated the fixed effects meta-analysis summary of the five studies. All calculations were done in Excel, and results were considered to be statistically significant at a two-sided threshold of P=.05. Results-Five randomized controlled clinical trials enrolling 5,577 patients were included. HCQ was associated with a 24% reduction in COVID-19 infection, hospitalization or death, P=.025
Conflicts of Interest Dr. Risch acknowledges past advisory consulting work with two of the more than 50 manufacturers of hydroxychloroquine, azithromycin and doxycycline. This past work was not related to any of these medications and was completed more than two years ago. He has no ongoing, planned or projected relationships with any of these companies, nor any other potential conflicts-of-interest to disclose. None of the other authors have any potential conflicts of interest to disclose. Key Messages Box: What is already known on this topic • Various government, clinical and research entities have been trying to evaluate the degree of benefit of hydroxychloroquine in early COVID-19 outpatient treatment. • Seven nonrandomized but controlled clinical trials to date have shown significant reductions in hospitalization and mortality with early ambulatory hydroxychloroquine use, but individual randomized outpatient trials have not shown statistical significance of benefit with these or other outcomes. What this study adds • The five outpatient randomized controlled studies to date examining new infection, hospitalization or mortality together show statistically significant evidence of reduced risk, RR=0.76 (95% CI 0.59 to 0.97). • No serious adverse cardiac events were reported in any of the studies. • The combined literature of seven nonrandomized controlled trials and five randomized controlled trials provides substantial and statistically significant evidence of benefit..
References
Arshad, Kilgore, Chaudhry, Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2020.06.099
Barbosa Esper, Da Silva, Costa Oikawa, Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine, Preprints, doi:10.21203/rs.3.rs-70219/v2
Benson, Hartz, A comparison of observational studies and randomized, controlled trials, N Engl J Med, doi:10.1056/NEJM200006223422506
Bernaola, Mena, Bernaola, Observational study of the efficiency of treatments in patients hospitalized with Covid-19 in Madrid, Preprints, doi:10.1101/2020.07.17.20155960
Brouqui, Gatineau, Raoult, Velthuis, Aj et al., Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture, New Microbes New Infect, doi:10.1016/j.nmni.2020
Catteau, Dauby, Montourcy, Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.10614422COVID-19RISK
Concato, Shah, Horwitz, Randomized, controlled trials, observational studies, and the hierarchy of research designs, N Engl J Med, doi:10.1056/NEJM200006223422507
Dersimonian, Laird, Meta-analysis in clinical trials revisited, Contemp Clin Trials, doi:10.1016/j.cct.2015.09.002
Dersimonian, Laird, Meta-analysis in clinical trials, Control Clin Trials, doi:10.1016/0197-2456(86
Horby, Lim, Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report, N Engl J Med, doi:10.1056/NEJMoa2021436
Ip, Ahn, Zhou, Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study, Preprints, doi:10.1101/2020.08.20.20178772
Lagier, Million, Gautret, Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med Infect Dis
Lauriola, Pani, Ippoliti, Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID-19 patients, Clin Transl Sci, doi:10.1111/cts.12860
Ly, Zanini, Laforge, Pattern of SARS-CoV-2 infection among dependant elderly residents living in retirement homes in Marseille, France, Preprints
Mccullough, Kelly, Ruocco, Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection, Am J Med, doi:10.1016/j.amjmed.2020.07.003
Mikami, Miyashita, Yamada, Risk factors for mortality in patients with COVID-19 in New York City, J Gen Intern Med, doi:10.1007/s11606-020-05983-z
Mitjà, Corbacho-Monné, Ubals, Hydroxychloroquine for early treatment of adults with mild COVID-19: A randomized-controlled trial, Clin Infect Dis, doi:10.1093/cid/ciaa1009
Park, Decloedt, Rayner, Cotton, Mills, Clinical trials of disease stages in COVID 19: complicated and often misinterpreted, Lancet Glob Health, doi:10.1016/S2214-109X(20)30365-X
Rajasingham, Bangdiwala, Nicol, Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial, N Engl J Med, doi:10.1101/2020.09.18.20197327v1
Skipper, Pastick, Engen, Hydroxychloroquine in nonhospitalized adults with early COVID-19: A randomized trial, Ann Intern Med, doi:10.7326/M20-4207
Sulaiman, Mohana, Alawdah, The effect of early hydroxychloroquine-based therapy in COVID-19 patients in ambulatory care settings: A nationwide prospective cohort study, Preprints, doi:10.1101/2020.09.09.20184143
Watanabe, Efficacy of hydroxychloroquine as prophylaxis for Covid-19, Preprints
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit